Nurix Ends Zelebrudomide Development

Company Nurix Therapeutics Event Type Program Discontinuation Modality Targeted protein degradation; dual BTK and IKZF1/3 cereblon-based degrader Asset NX-2127 (zelebrudomide); bexobrutideg (NX-5948) as portfolio context Target BTK; IKZF1; IKZF3 Disease Area B-cell malignancies (CLL/SLL, lymphoma) Summary Nurix Therapeutics discontinued further clinical development of NX-2127, or…